Search results
Results from the WOW.Com Content Network
Dupilumab is a monoclonal antibody that acts to inhibit part of the inflammatory pathway. [9] Dupilumab is the first treatment for prurigo nodularis approved by the FDA. [10] Prurigo nodularis is a rare skin disease that causes hard, itchy lumps (nodules) to form on the skin. [10]
The approval is based on the two-part (Part A and B) EoE KIDS Phase 3 trial in children aged 1 to 11 years, which established a bridge showing the response to Dupixent in children with EoE is similar to that of the approved adult and adolescent populations. In Part A, children who received a higher dose of Dupixent (n=37) based on a weight ...
Mepolizumab was approved for medical use in the European Union in December 2015. [5] In September 2020, mepolizumab was approved in the United States to treat adults and children aged twelve years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease. [5]
Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). [7] [8] It is an interleukin-13 antagonist. [7]
In August 2023, the FDA approved canakinumab for the symptomatic treatment of adults with gout flares in whom nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate based on three studies.
In February 2024, the US Food and Drug Administration (FDA) added an indication for immunoglobulin E-mediated food allergy for the reduction of allergic reactions, including anaphylaxis, which may occur with accidental exposure to one or more foods. [12] Omalizumab can be used as a monotherapy or in combination with oral immunotherapy. [21]
In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...
Zepbound is FDA-approved for weight loss in adults with obesity or overweight who have a weight-related condition. The side effects of semaglutide are quite similar to those of tirzepatide, as the ...